Immune-Mediated Dermatology Reactions IMFINZI and IMJUDO can cause immune-mediated rash or dermatitis. Exfoliative dermatitis, including Stevens-Johnson Syndrome (SJS), drug rash with eosinophilia ...

Durvalumab (Imfinzi) is a PD-L1–blocking antibody that has 3 indications for non–small cell lung cancer (NSCLC). February ...

WILMINGTON, Del., June 01, 2025--(BUSINESS WIRE)--Positive results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s IMFINZI ® (durvalumab) in combination ...

Imfinzi combined with FLOT chemotherapy improved EFS in resectable gastric/GEJ adenocarcinoma, with no new safety signals observed. Adverse effects were comparable between Imfinzi and placebo arms, ...

AstraZeneca’s immunotherapy Imfinzi has proven it can help certain patients with early-stage stomach cancer, according to results from a phase 3 study. Adding Imfinzi to the chemotherapy regimen ...

Recommendation based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death for the Imfinzi regimen vs. neoadjuvant ...

Positive results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s IMFINZI ® (durvalumab) in combination with standard-of-care FLOT (fluorouracil ...

AstraZeneca (AZ) has announced that its Imfinzi (durvalumab)-based perioperative regimen has been recommended for approval by the European Medicines Agency’s human medicines committee to treat adults ...